To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Bristol Myers Squibb appointed Nathan Pennell, MD, PhD, FASCO, as SVP, worldwide head of medical affairs for hematology and oncology, effective August 18. Nucleus RadioPharma hired former Food and ...

Our Bristol Myers Squibb Operating Income Comparison dashboard has more details. The company’s earnings stood at $2.97 on a per-share and reported basis in 2022, compared to the $2.02 figure in ...

Bristol Myers Squibb’s revenue of $11.9 billion in Q2 was up 2% y-o-y, and its EPS of $1.93 reflected an 18% growth. This compares with our estimates of $11.5 billion and $1.86, respectively.